Patents by Inventor Thomas Jorg Mehrling

Thomas Jorg Mehrling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for treating lymphoma or a T-cell malignant disease
    Patent number: 12377076
    Abstract: The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patients platelet count.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: August 5, 2025
    Assignee: Purdue Pharma L.P.
    Inventors: Katarina Hilgier, Francisco Ibanez Lopez, Thomas Jorg Mehrling
  • Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
    Patent number: 12370178
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Grant
    Filed: January 25, 2024
    Date of Patent: July 29, 2025
    Assignee: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • Compounds for treating brain cancer
    Patent number: 12370177
    Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof: for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumor, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: July 29, 2025
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Claudio Festuccia
  • Tinostamustine for use in treating sarcoma
    Patent number: 12257237
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: March 25, 2025
    Assignee: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • COMBINATION COMPRISING A GLUCOCORTICOID AND EDO-S101
    Publication number: 20250049762
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: July 17, 2024
    Publication date: February 13, 2025
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
    Publication number: 20250009715
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: June 14, 2024
    Publication date: January 9, 2025
    Applicant: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA
    Publication number: 20240316009
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Application
    Filed: January 25, 2024
    Publication date: September 26, 2024
    Applicant: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • Combination comprising a glucocorticoid and EDO-S101
    Patent number: 12064417
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: August 20, 2024
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • TINOSTAMUSTINE FOR USE IN TREATING OVARIAN CANCER
    Publication number: 20240261265
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of ovarian cancer in a patient in need thereof.
    Type: Application
    Filed: January 4, 2024
    Publication date: August 8, 2024
    Applicant: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • Pharmaceutical combinations for treating cancer
    Patent number: 12048688
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: July 30, 2024
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • COMPOUNDS FOR TREATING TNBC
    Publication number: 20240139155
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
    Type: Application
    Filed: September 12, 2023
    Publication date: May 2, 2024
    Applicant: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia
    Patent number: 11918558
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: March 5, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • Tinostamustine for use in treating ovarian cancer
    Patent number: 11896583
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of ovarian cancer in a patient in need thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 13, 2024
    Assignee: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • Compounds for treating TNBC
    Patent number: 11786509
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: October 17, 2023
    Assignee: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • COMBINATION COMPRISING A GLUCOCORTICOID AND EDO-S101
    Publication number: 20230285363
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: December 19, 2022
    Publication date: September 14, 2023
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • TINOSTAMUSTINE FOR USE IN TREATING SARCOMA
    Publication number: 20230277507
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.
    Type: Application
    Filed: February 13, 2023
    Publication date: September 7, 2023
    Inventor: Thomas Jorg Mehrling
  • PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
    Publication number: 20230241033
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: December 22, 2022
    Publication date: August 3, 2023
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • COMPOUNDS FOR TREATING TNBC
    Publication number: 20230080216
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
    Type: Application
    Filed: August 11, 2022
    Publication date: March 16, 2023
    Inventor: Thomas Jorg Mehrling
  • COMPOUNDS FOR TREATING BRAIN CANCER
    Publication number: 20230049350
    Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof: for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumour, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: July 27, 2022
    Publication date: February 16, 2023
    Inventors: Thomas Jorg Mehrling, Claudio Festuccia
  • Tinostamustine for use in treating sarcoma
    Patent number: 11576899
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 14, 2023
    Assignee: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling